Studies suggest Tesamorelin, which may act as a GHRH analog, may have the same properties as GHRH and other GHRH analogs, such as Sermorelin, GRF (1-29), CJC-1295, and so on. Researchers speculate Tesamorelin may be rendered more stable in plasma after being combined with trans-3-hexanoic acid, which appears to increase the compound’s half-life. Scientists hypothesize Tesamorelin, like CJC-1295, may maintain the physiological activity of GHRH and, as a result, may have fewer drawbacks than comparable compounds that eliminate normal pulsatile growth hormone (GH) production. This is the case even though Tesamorelin’s half-life is suggested to be longer than CJC-1295’s.
Tesamorelin and Lipodystrophy
Research suggests Tesamorelin’s most important property is in mitigating HIV-associated Lipodystrophy impacts. This condition may develop due to HIV infection or as a negative reaction to antiretroviral compounds. Studies suggest Tesamorelin may most often be used in animal research models with this condition. Lipodystrophy is characterized by abnormal fat accumulation in the abdominal region and other body parts. Even though the physiological mechanism that is responsible for this is not completely known, it is believed that protease inhibitors that are routinely used may have a critical role in the pathogenesis of Lipodystrophy [i].
Diet, exercise, and a small number of compounds that were not very successful were the original options tested on Lipotystrophy subjects. Research suggested that using Tesamorelin appeared to lead to a roughly 20% reduction in adiposity in this cohort [i]. Recent studies suggest the fat-burning potential of Tesamorelin may be nearly four times greater than that of all the other compounds available combined [ii].
Tesamorelin and the Heart
Test subjects affected by HIV may have an elevated risk of developing cardiovascular disease (CVD), partly because of excessive fat deposition and partly because of the activities of antiretroviral compounds themselves. Both of these factors might contribute to the increased risk. After highly active antiretroviral compounds (HAART), preventing cardiovascular disease in HIV-positive test subjects is considered by scientists to be the most significant intervention for long-term well-being.
Research on HIV-positive subjects speculated that in addition to potentially lowering levels of Lipodystrophy, Tesamorelin might also lower levels of triglycerides, total cholesterol, and non-HDL-C. Studies suggest a correlation between a drop in triglyceride levels and a reduction of 15% in visceral adipose tissue caused by Tesamorelin [3, 4].
It is important to note that inflammation has been linked to ectopic fat accumulation, which may be seen in Lipodystrophy. Inflammation of any form is considered a risk factor for cardiovascular disease. There is an independent link between visceral adipose tissue, fat in the liver, and epicardial fat with an increased risk of cardiovascular disease (CVD). Scientists hypothesize Tesamorelin may directly reduce inflammation and a subject’s risk of developing cardiovascular disease by lowering the amount of ectopic fat deposited in the body.
Tesamorelin and Growth Hormone
New research suggests that highly active antiretroviral compounds (HAART) may be connected with various endocrine and metabolic issues, including a lack of growth hormone (GH). It would seem that the pituitary gland is changed in HIV infection, and as a result, roughly one-third of HIV test subjects receiving HAART exhibit some GH shortage [iii]. Tesamorelin may mitigate this shortage, as researchers suggest.
Tesamorelin and Peripheral Nerves
Damage to periphery nerves might result from traumatic events, diabetes, or surgical procedures. As nerve cells are considered difficult to regenerate, it may often result in significant issues with both motor and sensory function in the afflicted region. However, research suggests that modifying growth hormones may ameliorate peripheral nerve damage and enhance both the pace and degree of recovery, suggesting a possible link in Tesamorelin [iv].
Tesamorelin and Dementia
There is new speculation that GHRH analogs, such as Tesamorelin, may improve cognition in subjects in the early stages of dementia. Tesamorelin and other GHRH analogs may impact dementia by increasing brain gamma-aminobutyric acid (GABA) levels and decreasing myo-insoitol (MI) levels, as suggested by the findings of a large, randomized, double-blind, placebo-controlled study done at the University of Washington School of Medicine over twenty weeks. [v]
Research Concerning Tesamorelin
Studies suggest Tesamorelin may be an appealing candidate for current clinical research. It is now being investigated for its potential to promote the recovery of peripheral nerves after damage, to delay the course of dementia, and minimize the risk of developing cardiovascular disease in HIV subjects.
More investigation is required to explore its potential in scientific research, and these studies must continue. Only academic and scientific institutions are allowed to use Tesamorelin for sale online. If you are a licensed professional interested in purchasing Tesamorelin peptides for your clinical studies, visit Biotech Peptides. Please note that none of the items mentioned are approved for human or animal consumption. Laboratory research chemicals are only for in-vitro and in-lab use. Any kind of physical introduction is illegal. Only authorized academics and working professionals may make purchases. The content of this article is intended only for instructional purposes.
References
[i] Clinical Review Report: Tesamorelin (Egrifta). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2016.
[ii] A. Mangili, J. Falutz, J.-C. Mamputu, M. Stepanians, and B. Hayward, “Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat,” PloS One, vol. 10, no. 10, p. e0140358, 2015. [PubMed]
[iii] V. Rochira and G. Guaraldi, “Growth hormone deficiency and human immunodeficiency virus,” Best Pract. Res. Clin. Endocrinol. Metab., vol. 31, no. 1, pp. 91–111, 2017. [PubMed]
[iv] S. H. Tuffaha et al., “Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury,” Expert Opin. Ther. Targets, vol. 20, no. 10, pp. 1259–1265, Oct. 2016. [PubMed]
[v] S. D. Friedman et al., “Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging,” JAMA Neurol., vol. 70, no. 7, pp. 883–890, Jul. 2013. [PubMed]